Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps
Chupp G, Alobid I, Lugogo N, Kariyawasam H, Bourdin A, Chaker A, Smith S, Sousa A, Mayer B, Chan R, Matucci A. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps. The Journal Of Allergy And Clinical Immunology In Practice 2023, 11: 3504-3512.e2. PMID: 37586475, DOI: 10.1016/j.jaip.2023.08.015.Peer-Reviewed Original ResearchConceptsSevere chronic rhinosinusitisOral corticosteroid doseSystemic corticosteroidsNasal polypsChronic rhinosinusitisCorticosteroid doseSinus surgerySCS useTreatment responseLong-term adverse effectsPlacebo treatment responsePrior sinus surgeryPatient baseline characteristicsBlood eosinophil countsSystemic corticosteroid useMepolizumab efficacyCorticosteroid useWeek 52Baseline characteristicsEosinophil countClinical benefitCare treatmentMepolizumabRhinosinusitisPlaceboRemission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Pavord I, Gardiner F, Heaney L, Domingo C, Price R, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Frontiers In Immunology 2023, 14: 1150162. PMID: 37122713, PMCID: PMC10131245, DOI: 10.3389/fimmu.2023.1150162.Peer-Reviewed Original ResearchConceptsSevere eosinophilic asthmaClinical remissionEosinophilic asthmaRemission definitionsClinical practiceAsthma Control Test scoresBetter ACT scoresProportion of patientsSubset of patientsACT scoreMepolizumab therapyMepolizumab treatmentOral corticosteroidsPrior exacerbationsOC useSevere asthmaBaseline characteristicsExpiratory volumeLung functionRemission outcomesMedical recordsDisease progressionTreatment outcomesRemissionTreatment goals